Collagen-induced arthritis in DBA/1 mice is a model of paw swelling and higher levels of anti-collagen antibody. rheumatoid arthritis with marked synovitis and erosions.
Introduction
advantages over systemic delivery. Pathogenic lymphoRheumatoid arthritis (RA) is a common chronic autocytes have been shown passively to transfer autoimmune immune disease for which there is currently a lack of diseases such as arthritis or diabetes in an organ-specific effective therapy capable of preventing long-term profashion into severe combined immunodeficient (SCID) gression and joint damage. Recent work on the pathogenmice or syngeneic mice that are immune depleted. 9, 10 esis of RA has suggested a number of new therapeutic These antigen-specific lymphocytes migrate specifically possibilities. 1 to their target organ causing disease. We have previously Transforming growth factor ␤1 (TGF ␤1) is secreted as shown that infection of arthritogenic splenocytes with a latent cytokine which becomes active at sites of retroviruses expressing a monomeric form of the human inflammation by proteolytic cleavage, low pH or other p75 TNF receptor (TNF-R) can inhibit the transfer of mechanisms. 2, 3 TGF ␤1 can regulate cell proliferation, arthritis into SCID mice. 11 In an extension to those studextracellular matrix production and degradation of cartiies, here we also demonstrate that amelioration of establage, and has several inhibitory functions on the immune lished arthritis, in DBA/1 mice, can be achieved by system. 3 TGF ␤1 has been detected in synovial fluid of directly expressing a potent inhibitory cytokine, ie TGF rheumatoid arthritis patients, mostly in its latent form. 4 ␤1, in the population of lymphoid cells carrying the disAcid-activated TGF ␤1 has been used to modulate colease. These cells are mobile and can therefore reach all lagen-induced arthritis (CIA) in DBA/1 mice 5 and in a joints and lymphoid organs involved in delivering the rat polyarthritis model. 6, 7 therapeutic agent locally at high concentrations. MoreThe important role of TGF ␤1 in inflammation has been over, genetically delivered TGF ␤1 is produced in a latent clearly demonstrated in knockout mice lacking the TGF form which becomes biologically active at sites of ␤1 gene after homologous recombination. These mice inflammation. showed multifocal inflammatory disease accompanied by overexpression of proinflammatory cytokines such as Results IFN-␥ , TNF and MIP-1␣. 8 Due to the importance of cytokines in normal immune
We investigated whether cells of the immune system functions, systemic cytokine blockade may lead to genresponsible for the development of CIA in DBA/1 mice eralized immunosuppression. Thus any therapeutic could deliver immunomodulatory molecules that affect the course of disease. We used the cytokine TGF ␤1 which is known to have suppressive effects on immune mice reactivated in vitro with bovine collagen type II. This procedure ensures that antigen-specific cells proliferate at the time of infection, which is a requirement for successful retroviral integration.
Prevention of transfer of arthritis from DBA/1 to SCID mice Splenocytes from arthritic DBA/1 mice are capable of transferring disease to SCID mice. We have previously shown that this transfer is not affected by infection with a retrovirus carrying either the HSV thymidine kinase gene or the bacterial ␤-galactosidase gene. However, the expression of a soluble form of the monomeric human p75 TNF receptor inhibited arthritis transfer. 11 We tested whether TGF ␤1 expressed from a retroviral vector could have an effect. Table 1 shows that TGF ␤1-infected arthritogenic splenocytes are inhibited from transferring the disease to SCID mice. This inhibition was clearly demonstrated by a lack of hind paw swelling and a reduction in anti-collagen Ab levels.
Arthritogenic splenocytes infected with TGF ␤1 expressing retrovirus inhibit exacerbation of established disease Having shown that TGF ␤1 was inhibitory in the arthritis transfer model we investigated whether delivering it with arthritogenic lymphocytes could have an effect on established disease. Arthritic mice at day 4 or 5 after onset were injected intraperitoneally with TGF ␤1-infected or non-infected arthritogenic splenocytes. Transfer of non-infected arthritogenic splenocytes had an had an anti-inflammatory effect and ameliorated the clinical score (Figures 1-3 ). Interestingly, there was also a transient decrease in the serum levels of anti-collagen Ab ( Figure 4 ). TGF ␤1 levels in the serum of TGF ␤1-of disease. The inhibition in anti-collagen Ab levels seen with splenocytes expressing TGF ␤1 (Figure 4 ) was reproengineered splenocyte-treated animals was higher (P = 0.022) than in untreated or mice treated with non-infected duced using purified T cells (P = 0.02; Figure 5 ). This result indicates that T cells alone can serve as carriers for arthritogenic splenocytes (Table 2) .
To determine whether the transient decrease in antitherapeutic genes. Using assessment of clinical score, which awards a collagen antibodies had an effect only on the B cells transferred within the splenocyte population, we purified T number from 1 to 3 to the degree of redness, swelling and deformity of normal contours to each extremity, we cells on nylon wool columns after infection with TGF ␤1 retrovirus and assessed their effect on anti-collagen antidetermined that from day 12 onwards after transfer of splenocytes the difference between the non-infected body levels after transfer to DBA/1 mice after the onset CIA (n = 6) 6/6 2.48 ± 0.08 14443 ± 13614 CIA + TGF␤1 (n = 9) 3/9 2.08 ± 0.04* 10102 ± 5646 *P = 0.0007 Paw swelling was determined at day 12 after transfer, anti-collagen antibody was determined at the termination of the experiment (day 15 after transfer). The base line of paw thickness in normal, age-matched SCID mice, was 2.0 ± 0.08 mm. The results were statistically analysed using the Mann-Whitney non-parametric test. splenocytes and the TGF ␤1-infected splenocytes was secreted by normal human fibroblasts (slot 6). There is statistically significant (P = 0.02; Figure 3 ). no activity in the 90 kDa molecular weight area correAs a control for the effect of retroviral infection, we sponding to MMP9 which is secreted by human melaused a high titer retrovirus producing a monomeric p75 noma cells (slot 5). Scanning of the zymogram (Figure 6 TNF-R, which we have previously used in our studies in panel B) showed that the gelatinolytic activity in SCID mice. 11 While we could detect serum levels of this inflamed paws of TGF ␤1-treated mice was reduced to protein for up to 12 weeks, we have been unable to find between 40 and 60% (slots 3 and 4) as compared with the any beneficial effect of this monomeric molecule on estabactivity seen in an untreated arthritic joint (slot 2). lished disease (not shown).
Decrease of gelatinase activity in paws of TGF ␤1-Discussion treated DBA/1 mice In addition to its immuno-inhibitory actions, TGF ␤1 has TGF ␤1 is known to inhibit the proliferation of lymphocytes, deactivates or suppresses the production of hydrobeen shown to increase the production of collagen by chondrocytes and it may have opposing effects to the gen peroxide in activated macrophages, down-regulates the effects of Th1 cytokines such as IFN␥ and IL-2, catabolic cytokine IL-1. We assessed directly whether TGF ␤1 affected gelatinolytic activity in inflamed joints.
inhibits the adhesion of leukocytes to endothelial cells, decreases protease activity and increases the expression Figure 6 shows the zymogram obtained from extraction of metalloproteases (MMPs) from hind paws from of collagens, proteoglycan, fibronectin and protease inhibitors such as TIMP-1. 3, 13, 14 In addition, TGF ␤1 is arthritic DBA/1 mice. Normal mice paws show no detectable levels of gelatin activity (slot 1) while all mitogenic for osteoblasts and augments the production of cartilage proteins. 15 It is therefore a potential therapeutic inflamed joints (slots 2-4) show gelatinase activity which could be inhibited by EDTA (not shown). Three peaks of agent for autoimmune disease involving cartilage degradation and bone destruction such as RA. activity are seen; one appears as a smear about 200 kDa, which may correspond to described membrane-bound Activated recombinant TGF ␤1 was previously shown to be effective in treatment of CIA in DBA/1 mice. When gelatinases, 12 and two discrete bands appear at 55 kDa. The latter comigrate with active and inactive MMP2 used preventively, TGF ␤1 at 5 g per day also down- models of systemic lupus erythematosus 16, 17 and inflammatory bowel disease. 18 In the first model TGF ␤1 injection blocked Ig production in the treated animals. fer model to SCID mice. 11 The serum levels of this TNF antagonist did not correlate with the therapeutic outcome, suggesting that the action was local. Moreover, a decrease in the anti-collagen Ab level correlated with the regulated the anti-collagen Ab titers while it was ineffective at blocking Ab production when administered 2 to therapeutic effect. In the experiments reported here using TGF ␤1 retrovirus ex vivo, the transfer of arthritis was 3 weeks after disease induction. 5 Activated (acid-treated) recombinant or natural TGF ␤1 increased synovitis in rats inhibited, however, its effect on anti-collagen Ab was not statistically significant, suggesting that the therapeutic when directly injected intra-articularly 7 but had a therapeutic effect when injected systemically. 6 These results effect is via a different mechanism than the one used by
Figure 6 TGF ␤1 inhibits gelatinase activity in inflamed paws. Zymogram analysis was described in Materials and methods. (a) Molecular weight markers (M); normal paw (slot 1); arthritic paw (slot 2); arthritic paw of TGF ␤1-treated animals (slots 3 and 4); supernatant from human melanoma cells (slot 5) and supernatant from human fibroblast cells (slot 6). (b) Scanning profiles from the MMP2 area showing slot 2 (dashed line), slot 3 (solid line) and slot 4 (dotted line).
the soluble TNF-R in this model. In the SCID transfer whereas in lymph nodes it inhibits. Its action also varies if it is provided endogenously or exogenously in an model of arthritis the immune/inflammatory reaction resembles a flare of rheumatoid arthritis which is differactive form. 26 Whether this differential effect depends on the interaction of TGF ␤1 with distinct components of the ent to the established disease model where inflammation is active, and cell recruitment of neutrophils and cartilage extracellular matrix or different receptors in each lymphoid organ is presently unknown. Thus the lack of a clear destruction has begun.
At the onset of disease in DBA/1 mice we demoneffect of TGF ␤1 on anti-collagen Ab production in the SCID transfer model and a transient blocking effect in strated that TGF ␤1 was capable of inhibiting the exacerbation caused by the injection of additional arthritogenic the syngeneic exacerbation model may relate to different interactions of B cells in different lymphoid organs trafsplenocytes by inhibiting spreading of the disease to additional joints, having an anti-inflammatory effect, ficking in the different strains of mice; in addition, TGF ␤1 may differentially affect B cells at different stages of transiently decreasing the anti-collagen antibody titer and decreasing the gelatinase activity in arthritic joints.
maturation. Histological assessment of arthritic joints 45 days after The transient effect on anti-collagen Ab levels may reflect the decrease to normal serum levels of TGF ␤1 seen on transfer indicated that all joints were either moderately or severely damaged by erosion and cell infiltration, and day 45 after onset. Whether this is related to the rejection of cells expressing a human protein is currently there was a lower score of severity in the joints of mice transferred with splenocytes expressing TGF ␤1, but this unknown.
Purified collagen-specific T cells infected with TGF ␤1 difference was not statistically significant (data not shown). Assessment of the joints at earlier time-points were sufficient to decrease the anti-collagen Ab levels as measured at day 15 after transfer.
could have shown a clearer score difference. The inhibition of gelatinolytic activity following TGF Such an effect on B cell function had been achieved only during prevention of CIA with anti-gp39 mono-␤1 gene therapy may relate to the reported induction of TIMP-1 in differentiated chondrocytes by this molecule, 14 clonal Ab, 19 or with gene therapy with monomeric TNF-R in the CIA transfer model into SCID mice 11 but not at which is probably mediated in part by IL-11. 27 Other additional beneficial anabolic effects of TGF ␤1 on onset with TGF ␤1 protein 5 or during treatment with anti-TNF antibodies. 20 It is possible that this effect requires cartilage metabolism, such as induction of collagen and proteoglycan synthesis, may also be important. cognate recognition between T and B cells and the interaction with specific stromal or antigen-presenting cells in
The latency of TGF ␤1 is an important biological safety device. This cytokine is expressed in its latent form and lymphoid organs. Down-regulation of the humoral response to collagen is important since the pathology of becomes activated in vivo by proteases, sialidases which are present at sites of inflammation, and where a healing CIA is dependent on the complement cascade and is partly mediated by anti-collagen Abs. [21] [22] [23] process is necessary. 2, 3 This mechanism enables the cytokine to be activated in a site-specific fashion avoiding TGF ␤1 may lead to inhibition of B cell proliferation by apoptosis 24 or indirectly by inhibition of T helper funcirrelevant systemic action. Using genetically delivered TGF ␤1 has, therefore, important biological and tion. In experimental allergic encephalomyelitis, oral tolerance appears to be mediated by secretion of TGF ␤1 therapeutic implications. The adaptability of our approach, using pathogenic by T cells that migrate from the gut to the site of inflammation. 25 lymphocytes as carriers of therapeutic genes, to other autoimmune disease models, has recently received Recently it has been shown that TGF ␤1 has a differential effect on IgG2b secretion on B cells from spleen or further support by the work of others using established T cell clones or lines in adoptive transfer models of lymph nodes. In the spleen it stimulates secretion diabetes in NOD mice 9 and in a rat model of experiapproximately 3 weeks after immunization. Mice were maintained according to approved Home Office protomental allergic neuritis. 28 Quantitative studies should be performed using purcols and following Institute guidelines. The number of mice used in these studies was the minimum required to ified arthritogenic T cell clones or lines that could be characterized in vitro where the number of cells transachieve statistical significance in this study. ferred and the levels of expression could be monitored before adoptive transfer.
Culture of spleens cells with collagen and infection with retroviruses The possibility of using a chronic relapsing model of the disease 29 that resembles more closely the clinical Spleen cell suspensions were prepared from mice at 2-3 days after onset of arthritis, and incubated with collagen course of RA could be an advantage in order to transfer engineered cells between relapsing phases.
at 100 g/ml for 48 h at 37°C in a 10% CO 2 humidified incubator. When necessary, cells were infected with retroWe are expanding this gene therapy approach to other autoimmune disease models where the antigen driving viruses as follows: for the last 4 h of incubation with collagen the cells were centrifuged at 1000 g for 5 min, resusthe immune response is known, such as in experimental allergic encephalomyelitis. In a human setting, the autopended at 2 × 10 6 cells/ml in viral supernatants supplemented with DEAE dextran (Sigma, Poole, UK) at antigen is not always known, and therefore this approach may require the isolation of organ-specific autologous a final concentration of 70 g/ml. After 4 h, the cells were washed twice with DMEM and 10% FBS (GIBCO). The lymphocytes or genetic modification of peripheral blood lymphocytes. cells were resuspended in DMEM without serum at 5 × 10 7 /ml and 1 ml injected intraperitoneally into DBA/1 mice on day 4 or 5 after onset. Transfer to SCID
Materials and methods
mice was intraperitoneally as previously described. (Travenol; Fenwall Laboratories, Deerfield, IL, USA) col-59954; ATCC, Rockville, MD, USA), a 1.7 kb EcoRI fragumns. 33 The T cell-purified population was at least 95% ment was cloned into the EcoRI site of pBabe neo. Six hunpure as assessed by FACS using the hamster anti-mouse dred and seventy-one bp from the 5′ untranslated region CD3 monoclonal Ab 145 2C11. 34 of TGF ␤1 in pBabe neo were removed by restriction with XhoI (blunted with Klenow and dNTPs) and SnaBI folHistological assessment of joint destruction lowed by religation with T4 DNA ligase (enzymes were Affected hind paws were removed at post mortem (day purchased from New England Biolabs, Hitchin, UK or 45 after onset), fixed in 10% formalin in phosphate-buffBoehringher Mannheim, Lewes, UK). The obtained retroered saline (PBS) and decalcified in EDTA (5.5% in PBS). viral vector was named TGF ␤1 Babe neo (-5′UTR).
After embedding in paraffin, the paws were sectioned and stained with haematoxylin and eosin. Grading of the Tissue culture, harvesting of retroviral supernatants histological joint destruction was as previously The packaging cell line GPenvAM12 31 was maintained in described. 20 Briefly scores were as follows: mild: syno-DMEM, 10% newborn calf serum with glutamine, penicilvitis, cartilage loss and bone erosions limited to discrete lin and streptomycin (GIBCO, Paisley, UK). One day foci; moderate: synovitis and erosions present, normal before transfection with the retroviral constructs, cells joint architecture intact; and severe: synovitis, extensive were trypsinized and plated at 5 × 10 5 cells/9 cm diamerosions, joint architecture disrupted. eter dish. Four hours before the DNA was added, as a
In our experiments joints with mild pathology were not calcium phosphate precipitate, the medium was changed.
found. The proportion of joints in each mouse with modThe transfection with TGF ␤1 Babe neo (-5′UTR) was carerate and severe destruction was assessed. The data were ried out as previously described. 32 More than 30 cell statistically analysed using the Mann-Whitney non-paraclones resistant to 1 mg/ml G418 (Geneticin; GIBCO) metric test. were isolated and pooled as a population and were maintained in G418 at 0.5 mg/ml. These cells produced 7
ELISA assays ng/ml/10 6 cells/24 h TGF ␤1 after correction for the Estimation of anti-collagen type II antibodies was perforendogenous levels produced by this cell line. The viral med by direct ELISA as previously described, 10 using an supernatants were collected overnight from confluent 15 affinity purified mouse anti-collagen Ab as a standard. cm plates containing 12 ml medium with 10% fetal bov-TGF ␤1 concentration was assessed using a commercial ine serum (FBS) or 10% newborn calf serum without the ELISA from Promega (Madison, WI, USA) after actiselective drug. The supernatants were centrifuged at vation in vitro with acid. 1000 g for 10 min to remove the cellular debris, transferred to sterile tubes and snap-frozen on dry ice. These
Gelatinase activity in inflamed paws supernatants were stored at −70°C.
Inflamed hind paws were snap-frozen in liquid nitrogen and pulverized using a mechanic mortar. Proteases were extracted using Triton X100 (BDH Laboratory Supplies, Mouse immunization Ten-to 12-week-old male DBA/1 mice were injected at Poole, UK). 35 Heating of the tissue homogenate at 60°C gave similar relative activities. Gelatinases were assayed the base of the tail with 100 l of a solution containing 2 mg/ml native bovine type II collagen mixed 1:1 in using a zymogram on 8% SDS PAGE; gels were electrophoresed at 4°C. Gelatinase activity of supernatants Freund's complete adjuvant. 10 Onset of arthritis was
